{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events.","groupId":"OG000","lowerLimit":"8.1","upperLimit":"NA","value":"20.9"},{"groupId":"OG001","lowerLimit":"7.6","upperLimit":"20.1","value":"15.0"},{"groupId":"OG002","lowerLimit":"7.5","upperLimit":"21.2","value":"13.5"},{"comment":"The upper limit of 95% confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events.","groupId":"OG003","lowerLimit":"7.7","upperLimit":"NA","value":"14.5"},{"comment":"The median and upper limit 95% confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events.","groupId":"OG004","lowerLimit":"4.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"OS defined as the time from randomization until the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG000","title":"Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG001","title":"Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG002","title":"Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG003","title":"Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.","id":"OG004","title":"Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Population. Only those participants with documented death due to any cause have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 152 weeks","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}